<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04787913</url>
  </required_header>
  <id_info>
    <org_study_id>herdimm</org_study_id>
    <nct_id>NCT04787913</nct_id>
  </id_info>
  <brief_title>An Evaluation of a Dynamic Web-Based Visualization of Community Immunity</brief_title>
  <official_title>An Evaluation of a Dynamic Web-Based Visualization of Community Immunity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a PhD project conducted by Ms. Hina Hakim, supervised by Dr. Holly O. Witteman,&#xD;
      PhD, and co-supervised Dr. Daniel Reinharz, professors and researchers at the Faculty of&#xD;
      Medicine at Laval University. The purpose of this study is to evaluate the effects of&#xD;
      visualization conveying the concept of community immunity or herd immunity on risk perception&#xD;
      (towards individual, family, community and vulnerable people in communities) (primary&#xD;
      outcome) and on emotions, attitudes, knowledge, and behavioural intentions (secondary&#xD;
      outcomes).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Visualization is a powerful communication mechanism that uses pre-attentive processing to&#xD;
      communicate large amounts of information rapidly in understandable and compelling ways&#xD;
      (Healey and Enns 2012). A systematic review demonstrates that there are some interventions&#xD;
      available for conveying the concept of community immunity, and very few evaluate&#xD;
      interventions for their effects on vaccine intentions and uptake as well as their precursors,&#xD;
      such as knowledge, attitudes, knowledge and none on emotions (Hakim et al. 2018).&#xD;
&#xD;
      The purpose of this study is to evaluate the effects of visualization conveying the concept&#xD;
      of community immunity on risk perception (to individual, family, community and vulnerable&#xD;
      people in communities) (primary outcome) and on emotions, attitudes, knowledge, and&#xD;
      behavioural intentions (secondary outcomes).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>This study will be a multi-armed factorial randomized controlled trial. Each participant will be randomly allocated to focus on one of four possible vaccine-preventable diseases: measles, pertussis, flu (influenza), or a generic vaccine-preventable disease (hereby referred to as &quot;generic&quot;). All aspects of the study (visualization, questionnaire) will be focused on that one disease for that participant. The primary and secondary outcomes of the study which are risk perception, emotion, knowledge, trust in information provided, attitudes and a validated scale about vaccination (Betsch et al. 2018) will be assessed in an online questionnaire.&#xD;
Because three online visualizations are available only in English whereas our study will be conducted in both English and French, we will use slightly different randomization patterns for English- and French-speaking participants.</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>Single (Investigator)</masking>
    <masking_description>This will be a single-blinded study because we cannot mask participants to the fact that they have been randomized to a visualization e.g., about measles. However, participants will not necessarily know the purpose of the study arm to which they are assigned,and investigators will be blinded to study arm during data analysis (investigators are not aware of whether the next eligible participant will be receiving treatment or control intervention.)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Risk perception</measure>
    <time_frame>immediately after intervention or control</time_frame>
    <description>6 ad hoc questions assessing risk perception</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>emotions, attitudes, knowledge, and behavioural intentions</measure>
    <time_frame>immediately after intervention or control</time_frame>
    <description>ad hoc questions and 5C scale (Betsch et al.)</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Anticipated">5440</enrollment>
  <condition>Understanding of Community Immunity as a Concept</condition>
  <arm_group>
    <arm_group_label>controlgeneric</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English and French.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controlmeasles</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention provided. Participant answers outcome questions about measles. English and French.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controlpertussis</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention provided. Participant answers outcome questions about pertussis. English and French.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>controlflu</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention provided. Participant answers outcome questions about flu. English and French.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>herdimmgeneric</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Web-based application (main intervention) provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English and French.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>herdimmmeasles</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Web-based application (main intervention) provided. Participant answers outcome questions about measles. English and French.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>herdimmpertussis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Web-based application (main intervention) provided. Participant answers outcome questions about pertussis. English and French.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>herdimmflu</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Web-based application (main intervention) provided. Participant answers outcome questions about flu. English and French.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>robertkochgeneric</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Web-based application (comparator) provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sbsnewsgeneric</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Video (comparator) provided. Participant answers outcome questions about an unnamed vaccine-preventable disease. English only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>guardianmeasles</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Video (comparator) provided. Participant answers outcome questions about measles. English only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>theotheredmundmeasles</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Video (comparator) provided. Participant answers outcome questions about measles. English only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>publichealthagencycanadaflu</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Video (comparator) provided. Participant answers outcome questions about flu. English and French.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>herdimm</intervention_name>
    <description>In this visualization participants can build their own avatar representing themselves and 8 other avatars representing people around them, like their family or coworkers. Our visualization then uses these avatars in a brief narrated video explaining how herd immunity works.</description>
    <arm_group_label>herdimmflu</arm_group_label>
    <arm_group_label>herdimmgeneric</arm_group_label>
    <arm_group_label>herdimmmeasles</arm_group_label>
    <arm_group_label>herdimmpertussis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>guardianmeasles</intervention_name>
    <description>A screen capture of an interactive visualization: https://www.theguardian.com/society/ng-interactive/2015/feb/05/-sp-watch-how-measles-outbreak-spreads-when-kids-get-vaccinated</description>
    <arm_group_label>guardianmeasles</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>theotheredmundmeasles</intervention_name>
    <description>A gif showing measles spreading through populations with differing levels of vaccine coverage: https://imgur.com/gallery/8M7q8#J7LANQ4</description>
    <arm_group_label>theotheredmundmeasles</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>sbsnewsgeneric</intervention_name>
    <description>A video showing how herd immunity works in general: https://www.sbs.com.au/news/two-sydney-babies-too-young-to-be-vaccinated-infected-with-measles</description>
    <arm_group_label>sbsnewsgeneric</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>publichealthagencycanadaflu</intervention_name>
    <description>A video showing how herd immunity works in the context of influenza: https://www.canada.ca/fr/sante-publique/services/video/la-grippe-n-en-passez-pas-les-maux.html</description>
    <arm_group_label>publichealthagencycanadaflu</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>robertkochgeneric</intervention_name>
    <description>A web-based application showing how herd immunity works in general: http://rocs.hu-berlin.de/D3/herd/</description>
    <arm_group_label>robertkochgeneric</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Members of the general population in Canada&#xD;
&#xD;
          -  At least 18 years old&#xD;
&#xD;
          -  Able to provide free and informed consent&#xD;
&#xD;
          -  Able to read and understand French or English&#xD;
&#xD;
          -  Able to use a computer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - No internet access&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Holly Witteman, PhD</last_name>
    <phone>418-656-2131</phone>
    <phone_ext>403981</phone_ext>
    <email>holly.witteman.1@ulaval.ca</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 4, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>herd immunity</keyword>
  <keyword>community immunity</keyword>
  <keyword>web-based application</keyword>
  <keyword>visualization</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized data (answers to questions in the survey including socio-demographic information) will be deposited in a public repository (Dataverse de l'Universit√© Laval (Laval University)) which will allow data sharing with the scientific community. No information that would allow anyone to identify a person will be deposited in this public repository. Study protocol and statistical analysis plan have been deposited in Open Science Framework.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>As soon as possible upon completion of the study and posting of a preprint with results.</ipd_time_frame>
    <ipd_access_criteria>Freely available.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

